Pacific Biosciences of Ca... (PACB)
1.18
-0.09 (-7.09%)
At close: Apr 03, 2025, 3:59 PM
1.13
-4.24%
Pre-market: Apr 04, 2025, 07:09 AM EDT
-7.09% (1D)
| Bid | 1.13 |
| Market Cap | 351.47M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.59 |
| PE Ratio (ttm) | -0.74 |
| Forward PE | -2.5 |
| Analyst | Buy |
| Ask | 1.15 |
| Volume | 5,392,040 |
| Avg. Volume (20D) | 11,404,713 |
| Open | 1.17 |
| Previous Close | 1.27 |
| Day's Range | 1.17 - 1.26 |
| 52-Week Range | 1.08 - 3.70 |
| Beta | 2.03 |
About PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded...
Industry Medical - Devices
Sector Healthcare
IPO Date Oct 27, 2010
Employees 575
Stock Exchange NASDAQ
Ticker Symbol PACB
Website https://www.pacb.com
Analyst Forecast
According to 13 analyst ratings, the average rating for PACB stock is "Buy." The 12-month stock price forecast is $2, which is an increase of 69.49% from the latest price.
Stock ForecastsNext Earnings Release
Pacific Biosciences of California Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+25%
Pacific Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
1 month ago
+25%
Pacific Biosciences of California shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results. Also, Softbank added 20.45M shares in the company.
